Could a repurposed drug tame seizures in adult dravet patients?

NCT ID NCT05560282

Terminated Disease control Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested the drug fenfluramine (FINTEPLA) in adults with Dravet syndrome whose seizures were not controlled by other medications. The trial was open-label and added fenfluramine to existing treatments. It aimed to see if the drug could reduce monthly seizures by at least 50%. However, the study was terminated early with only 7 participants enrolled, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: fenfluramine (FINTEPLA)
What this could lead to: If it works, this could provide a new treatment option to reduce seizures in adults with Dravet syndrome who don't respond to current medications.
What could go wrong: This small, early-phase trial was terminated, so results are limited. Fenfluramine may cause side effects like appetite loss or heart valve issues, and its benefits in adults are not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DRAVET SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Dravet syndrome Epilepsies, Myoclonic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DRAVET SYNDROME DRAVET SYNDROME, INTRACTABLE

Contacts and locations

Locations

Toronto Western Hospital

Toronto, Ontario, M5T 2S8, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.